Loading…
Employees: 3,049
Size Integral Diagnostics (IDX.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $450M, the 272nd largest of 316 Australia companies the cockpit tracks. Shares closed at A$1.74 on 6 Nov 2026.
Performance Over six months the shares fell 20.6%, against -1.1% for the median peer and +4.1% for the Australia market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue grew 25.7% over the last twelve months (peer median +6.0%); the operating margin is 8.7% (peer median 8.0%).
Valuation It trades at 15.5× forward earnings against a peer median of 17.3× (7th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.0 points below its cost of capital (6.9% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$789M | A$789M | A$627M | A$470M | A$440M |
| Revenue growth | — | +26% | +34% | +7% | — |
| Gross profit | A$169M | A$169M | A$136M | A$104M | A$96.4M |
| EBITDA | A$143M | A$142M | A$114M | A$89.0M | A$82.0M |
| Net income | A$21.9M | A$21.9M | A$2.69M | -A$60.7M | A$25.0M |
| Free cash flow | A$45.6M | A$45.6M | A$14.0M | A$42.3M | A$23.1M |
| Capital expenditure | A$49.6M | A$49.6M | A$59.8M | A$23.9M | A$44.0M |
| Total debt | n/a | A$597M | A$585M | A$358M | A$365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IDX.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.3% | -5.7% | 5th lowest of 21 |
| 6-month return | -20.6% | -1.1% | 4th lowest of 19 |
| Distance from 52-week high | -35.8% | -23.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +25.7% | +6.0% | 6th highest of 21 |
| Operating margin | 8.7% | 8.0% | 10th highest of 21 |
| Forward P/E | 15.5× | 17.3× | 7th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 8.3% | 3.9% | 7th most demanding of 16 |
| Growth delivered (Del g) | +17.7% | +12.4% | 6th highest of 16 |
| Hurdle (Req g minus delivered) | -9.4 pp | -16.0 pp | 7th most demanding of 16 |
| ROIC minus cost of capital | -3.0 pp | -1.0 pp | 9th lowest of 20 |
| EV / EBITDA | 8.4× | 9.6× | 5th cheapest of 12 |
| Net debt / EBITDA | 3.8× | 0.9× | 3rd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 13.9× | 8.1% | +42.6% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 17.3× | 3.9% | +2.6% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 25.5× | 12.0% | -1.5% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | n/a | 22.4% | -5.8% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 18.5× | -5.5% | +17.9% |
| Oncology Institute STLN | United States | $362M | n/a | +38% | -4% | n/a | n/a | n/a |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $353M | +6% | 0% | -2% | n/a | -15.1% | +9.6% |
| NIOX NIOX.L | United Kingdom | $349M | +2% | +3% | 22% | 20.7× | 3.9% | +15.3% |
| Auna AUNA | United States | $346M | -8% | +17% | 13% | 4.7× | -10.5% | +24.4% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $324M | -7% | 0% | 31% | 9.6× | -12.3% | +15.4% |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |